Genomic-driven chemotherapy

Genomic-driven chemotherapy refers to a personalized neoadjuvant treatment strategy for patients with HER2-negative breast cancer, evaluated in the Phase 3 NCT01503970 trial. Developed by Gustave Roussy, this regimen assigns specific chemotherapy agents based on tumor genomic markers: the DLD30 (a 30-gene signature predicting docetaxel sensitivity) and TOP2A (Topoisomerase II alpha) expression. Patients with a high DLD30 score receive weekly paclitaxel followed by FEC (fluorouracil, epirubicin, and cyclophosphamide). Patients with high TOP2A expression receive the standard sequence of FEC followed by docetaxel. Patients with low scores for both markers are treated with a combination of docetaxel and capecitabine. This approach aims to improve pathological complete response (pCR) rates by tailoring cytotoxic therapy to the molecular profile of the individual tumor.

Other names

Genomic driven chemotherapy-Gustave Roussy, Cancer Campus, Grand Paris-breast cancerGenomic-driven chemotherapy regimenDLD30/TOP2A-driven chemotherapyNCT01503970 regimenNCT-01503970 regimenNCT 01503970 regimen